SpringWorks Therapeutics Inc (NASDAQ:SWTX)’s traded shares stood at 1.16 million during the last session, with the company’s beta value hitting 0.77. At the close of trading, the stock’s price was $54.14, to imply an increase of 0.20% or $0.11 in intraday trading. The SWTX share’s 52-week high remains $62.00, putting it -14.52% down since that peak but still an impressive 47.89% since price per share fell to its 52-week low of $28.21.
Analysts have given a consensus recommendation of Buy for SpringWorks Therapeutics Inc (SWTX), translating to a mean rating of 1.12. Of 3 analyst(s) looking at the stock, 0 analyst(s) give SWTX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy.
SpringWorks Therapeutics Inc (NASDAQ:SWTX) trade information
After registering a 0.20% upside in the last session, SpringWorks Therapeutics Inc (SWTX) has traded red over the past five days. The 5-day price performance for the stock is -2.85%, and 51.14% over 30 days. With these gigs, the year-to-date price performance is 49.85%.
The extremes give us $78 and $78 for target low and target high price respectively. As such, SWTX has been trading -44.07% off suggested target high and -44.07% from its likely low.
SWTX Dividends
SpringWorks Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
SpringWorks Therapeutics Inc (NASDAQ:SWTX)’s Major holders
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 6.54 million shares, or about 8.8715% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $246.53 million.
We also have Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the SpringWorks Therapeutics Inc (SWTX) shares. Going by data provided on Dec 31, 2024, Fidelity Growth Company Fund holds roughly 3.56 shares. This is just over 4.75% of the total shares, with a market valuation of $192.87 million. Data from the same date shows that the other fund manager holds a little less at 2.1, or 2.80% of the shares, all valued at about 113.58 million.
